ID   HCC827-HGF2
AC   CVCL_B7N3
DR   cancercelllines; CVCL_B7N3
DR   Wikidata; Q112929642
RX   PubMed=20716641;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 4893; HGF.
CC   Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2063 ! HCC827
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=20716641; DOI=10.1158/1535-7163.MCT-10-0481;
RA   Okamoto W., Okamoto I., Tanaka K., Hatashita E., Yamada Y., Kuwata K.,
RA   Yamaguchi H., Arao T., Nishio K., Fukuoka M., Janne P.A.,
RA   Nakagawa K.;
RT   "TAK-701, a humanized monoclonal antibody to hepatocyte growth factor,
RT   reverses gefitinib resistance induced by tumor-derived HGF in
RT   non-small cell lung cancer with an EGFR mutation.";
RL   Mol. Cancer Ther. 9:2785-2792(2010).
//